Comparative Pharmacology
Head-to-head clinical analysis: GLEOSTINE versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLEOSTINE versus TREANDA.
GLEOSTINE vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category C
Category C
Alkylating Agent
Alkylating Agent